[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.92.62. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 823
Citations 0
Correction
September 2015

Erratum in Table

JAMA Pediatr. 2015;169(9):878. doi:10.1001/jamapediatrics.2015.2429

In the Original Investigation titled “Treatment for Preventing Tuberculosis in Children and Adolescents: A Randomized Clinical Trial of a 3-Month, 12-Dose Regimen of a Combination of Rifapentine and Isoniazid” published online January 12, 2015, and in the March 2015 print issue of JAMA Pediatrics,1 a printing error occurred in Table 2. For the Treatment completion row, the difference (95% CI), which read “−7.2 (−2.0 to −2.5),” should be replaced with “−7.2 (−12.0 to −2.5).” This article was corrected online.

References
1.
Villarino  ME, Scott  NA, Weis  SE,  et al; International Maternal Pediatric and Adolescents AIDS Clinical Trials Group (IMPAACT); Tuberculosis Trials Consortium (TBTC).  Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr. 2015;169(3):247-255.
PubMedArticle
×